Pharmacokinetic properties of netilmicin in newborn infants

J. D. Siegel, G. H. McCracken, M. L. Thomas, N. Threlkeld

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Netilmicin and gentamicin susceptibilities of 258 gram-negative organisms and 25 strains of staphylococcus aureus were nearly identical. The pharmacokinetic properties of netilmicin were evaluated in 101 newborn infants and related to birth weight, gestational age, chronological age, and route of administration. Mean peak serum concentrations of 5.6 to 6.9 and 7.8 to 8.4 μg/ml were observed 30 min after 3- and 4-mg/kg doses, respectively, were given intramuscularly. The peak concentrations were directly related to gestational age. The average serum half-life values varied from 3.4 to 4.7 h and in general were inversely related to birth weight, gestational age, and postnatal age. The pharmacokinetics of netilmicin in 10 infants were similar after intramuscular and intravenous administration. A comparative study of netilmicin and gentamicin in seven neonates revealed greater variability in serum concentrations of gentamicin and a shorter half-life for netilmicin. There was evidence of accumulation of netilmicin in 12 low-birth weight, premature infants who received 4-mg/kg doses for an average of 6.4 days. Serum and urine levels of netilmicin were measured up to 11 days after discontinuation of the drug. These data are well characterized by a two-compartment model. Additional studies of efficacy and long-term toxicity of netilmicin in neonates are necessary.

Original languageEnglish (US)
Pages (from-to)246-253
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume15
Issue number2
StatePublished - 1979

Fingerprint

Netilmicin
Pharmacokinetics
Newborn Infant
Gentamicins
Gestational Age
Serum
Birth Weight
Half-Life
Low Birth Weight Infant
Premature Infants
Intravenous Administration
Staphylococcus aureus
Urine

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Pharmacokinetic properties of netilmicin in newborn infants. / Siegel, J. D.; McCracken, G. H.; Thomas, M. L.; Threlkeld, N.

In: Antimicrobial Agents and Chemotherapy, Vol. 15, No. 2, 1979, p. 246-253.

Research output: Contribution to journalArticle

Siegel, JD, McCracken, GH, Thomas, ML & Threlkeld, N 1979, 'Pharmacokinetic properties of netilmicin in newborn infants', Antimicrobial Agents and Chemotherapy, vol. 15, no. 2, pp. 246-253.
Siegel, J. D. ; McCracken, G. H. ; Thomas, M. L. ; Threlkeld, N. / Pharmacokinetic properties of netilmicin in newborn infants. In: Antimicrobial Agents and Chemotherapy. 1979 ; Vol. 15, No. 2. pp. 246-253.
@article{c865bcb95376494ab912fcb65f92005c,
title = "Pharmacokinetic properties of netilmicin in newborn infants",
abstract = "Netilmicin and gentamicin susceptibilities of 258 gram-negative organisms and 25 strains of staphylococcus aureus were nearly identical. The pharmacokinetic properties of netilmicin were evaluated in 101 newborn infants and related to birth weight, gestational age, chronological age, and route of administration. Mean peak serum concentrations of 5.6 to 6.9 and 7.8 to 8.4 μg/ml were observed 30 min after 3- and 4-mg/kg doses, respectively, were given intramuscularly. The peak concentrations were directly related to gestational age. The average serum half-life values varied from 3.4 to 4.7 h and in general were inversely related to birth weight, gestational age, and postnatal age. The pharmacokinetics of netilmicin in 10 infants were similar after intramuscular and intravenous administration. A comparative study of netilmicin and gentamicin in seven neonates revealed greater variability in serum concentrations of gentamicin and a shorter half-life for netilmicin. There was evidence of accumulation of netilmicin in 12 low-birth weight, premature infants who received 4-mg/kg doses for an average of 6.4 days. Serum and urine levels of netilmicin were measured up to 11 days after discontinuation of the drug. These data are well characterized by a two-compartment model. Additional studies of efficacy and long-term toxicity of netilmicin in neonates are necessary.",
author = "Siegel, {J. D.} and McCracken, {G. H.} and Thomas, {M. L.} and N. Threlkeld",
year = "1979",
language = "English (US)",
volume = "15",
pages = "246--253",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetic properties of netilmicin in newborn infants

AU - Siegel, J. D.

AU - McCracken, G. H.

AU - Thomas, M. L.

AU - Threlkeld, N.

PY - 1979

Y1 - 1979

N2 - Netilmicin and gentamicin susceptibilities of 258 gram-negative organisms and 25 strains of staphylococcus aureus were nearly identical. The pharmacokinetic properties of netilmicin were evaluated in 101 newborn infants and related to birth weight, gestational age, chronological age, and route of administration. Mean peak serum concentrations of 5.6 to 6.9 and 7.8 to 8.4 μg/ml were observed 30 min after 3- and 4-mg/kg doses, respectively, were given intramuscularly. The peak concentrations were directly related to gestational age. The average serum half-life values varied from 3.4 to 4.7 h and in general were inversely related to birth weight, gestational age, and postnatal age. The pharmacokinetics of netilmicin in 10 infants were similar after intramuscular and intravenous administration. A comparative study of netilmicin and gentamicin in seven neonates revealed greater variability in serum concentrations of gentamicin and a shorter half-life for netilmicin. There was evidence of accumulation of netilmicin in 12 low-birth weight, premature infants who received 4-mg/kg doses for an average of 6.4 days. Serum and urine levels of netilmicin were measured up to 11 days after discontinuation of the drug. These data are well characterized by a two-compartment model. Additional studies of efficacy and long-term toxicity of netilmicin in neonates are necessary.

AB - Netilmicin and gentamicin susceptibilities of 258 gram-negative organisms and 25 strains of staphylococcus aureus were nearly identical. The pharmacokinetic properties of netilmicin were evaluated in 101 newborn infants and related to birth weight, gestational age, chronological age, and route of administration. Mean peak serum concentrations of 5.6 to 6.9 and 7.8 to 8.4 μg/ml were observed 30 min after 3- and 4-mg/kg doses, respectively, were given intramuscularly. The peak concentrations were directly related to gestational age. The average serum half-life values varied from 3.4 to 4.7 h and in general were inversely related to birth weight, gestational age, and postnatal age. The pharmacokinetics of netilmicin in 10 infants were similar after intramuscular and intravenous administration. A comparative study of netilmicin and gentamicin in seven neonates revealed greater variability in serum concentrations of gentamicin and a shorter half-life for netilmicin. There was evidence of accumulation of netilmicin in 12 low-birth weight, premature infants who received 4-mg/kg doses for an average of 6.4 days. Serum and urine levels of netilmicin were measured up to 11 days after discontinuation of the drug. These data are well characterized by a two-compartment model. Additional studies of efficacy and long-term toxicity of netilmicin in neonates are necessary.

UR - http://www.scopus.com/inward/record.url?scp=0018408556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018408556&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 246

EP - 253

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -